Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Earnings Results, Misses Estimates By $0.20 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.20), FiscalAI reports. The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s revenue was up 65.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.12) earnings per share.

Kiniksa Pharmaceuticals International Trading Down 0.8%

KNSA opened at $47.39 on Tuesday. The company’s 50 day moving average is $42.83 and its 200 day moving average is $39.56. Kiniksa Pharmaceuticals International has a 12-month low of $18.25 and a 12-month high of $49.12. The company has a market cap of $3.59 billion, a price-to-earnings ratio of 105.31 and a beta of 0.06.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the sale, the chief financial officer owned 12,086 shares in the company, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the sale, the chief operating officer owned 16,666 shares in the company, valued at approximately $692,638.96. This represents a 41.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,823 shares of company stock valued at $5,244,967 over the last ninety days. 53.48% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. Virtu Financial LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth $267,000. Invesco Ltd. boosted its stake in shares of Kiniksa Pharmaceuticals International by 25.9% during the fourth quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock valued at $1,334,000 after purchasing an additional 6,656 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Kiniksa Pharmaceuticals International by 7.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after buying an additional 508 shares during the period. Empowered Funds LLC purchased a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth $51,000. Finally, XTX Topco Ltd bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at $291,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price target on the stock. The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.71.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.